PLRX vs GILD vs KO

For growth investors, Gilead Sciences, Inc.

(GILD) is the stronger pick with 2. 4% revenue growth year-over-year, versus 1. 9% for The Coca-Cola Company (KO). Gilead Sciences, Inc. (GILD) offers the better valuation at 18. 5x trailing P/E, making it the more compelling value choice. Analysts rate Gilead Sciences, Inc. (GILD) a "Buy" — based on 58 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Gilead Sciences, Inc.

(GILD) is the cheapest at 18. 5x versus The Coca-Cola Company at 27. 2x.

Over the past 5 years, Gilead Sciences, Inc.

(GILD) delivered a total return of +106. 5%, compared to -96. 6% for Pliant Therapeutics, Inc. (PLRX). Over 10 years, the gap is even starker: KO returned +121. 1% versus PLRX's -94. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), The Coca-Cola Company (KO) is the lower-risk stock at -0.

20β versus Pliant Therapeutics, Inc. 's 1. 14β — meaning PLRX is approximately -669% more volatile than KO relative to the S&P 500. On balance sheet safety, Pliant Therapeutics, Inc. (PLRX) carries a lower debt/equity ratio of 16% versus 133% for The Coca-Cola Company — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Gilead Sciences, Inc.

(GILD) is pulling ahead at 2. 4% versus 1. 9% for The Coca-Cola Company (KO). On earnings-per-share growth, the picture is similar: Gilead Sciences, Inc. grew EPS 1684% year-over-year, compared to 23. 6% for The Coca-Cola Company. Over a 3-year CAGR, KO leads at 3. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Gilead Sciences, Inc.

(GILD) is the more profitable company, earning 28. 9% net margin versus 0. 0% for Pliant Therapeutics, Inc. — meaning it keeps 28. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: GILD leads at 39. 7% versus 0. 0% for PLRX. At the gross margin level — before operating expenses — GILD leads at 78. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for GILD: 28.

3% to $161. 12.

In this comparison, GILD (2.

5% yield), KO (2. 5% yield) pay a dividend. PLRX does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, The Coca-Cola Company (KO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.

20), 2. 5% yield, +121. 1% 10Y return). Both have compounded well over 10 years (KO: +121. 1%, PLRX: -94. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (PLRX (Healthcare) and GILD (Healthcare) and KO (Consumer Defensive)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

GILD, KO pay a dividend while PLRX does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.